Phaseline

Targets › CASP3

CASP3 (Caspase-3): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Apr 2028.

Thiol protease that acts as a major effector caspase involved in the execution phase of apoptosis. Following cleavage and activation by initiator caspases (CASP8, CASP9 and/or CASP10), mediates execution of apoptosis by catalyzing cleavage of many proteins. (UniProt, P42574)

Open in Phaseline: the race on CASP3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tongji HospitalKD01
Conditionally replicative recombinant adenovirus with E3 region replaced by tBid apoptotic
CASP3Phase 1Cervical Cancer; Bladder Cancer (BC)Apr 2028

Conditions

Cervical Cancer (1) Bladder Cancer (BC) (1)

Modalities

other (1)

Companies

Tongji Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.